Specifically, anti-estrogens, aromatase inhibitors (AIs) and selective ER modulators have proven effective in the treatment of hormone receptor-positive breast cancer; however, a major clinical problem limiting the usefulness of endocrine therapy is tumor resistance (Schiff et al. 2004; Chu and Lu 2008). Here, ESR1 is linked to neoplasm.